A 2022 New England Journal of Medicine study (No Surprise: Single Dose Psilocybin for Treatment-Resistant Major Depression) found that a single 25-milligram dose of synthetic psilocybin provided significantly greater relief from treatment-resistant depression at week 3 compared to 10-milligram or 1-milligram placebo doses, with relief remaining stable through week 12.
factualpending
Speaker
Andrew HubermanEvidence Quote
“the change in baseline levels of depression...at week three following the psilocybin session was significantly better...people experienced more relief...from the 25 milligram dose than from the 1 milligram dose...They still saw a significant degree of depression relief 12 weeks after the single 25-milligram psilocybin dose session”
Created: 8/12/2026, 6:37:08 PM
Your notes
Loading notes...